Capstone Investment Advisors
MOLN

Capstone Investment Advisors’s Molecular Partners MOLN Stock Holding History

Capstone Investment Advisors’s Portfolio MOLN Stock Details MOLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-28,741
Closed -$589K – 2048
2021
Q2 		$589K Buy
+28,741
New +$570K ﹤0.01% 1355

Other funds holding MOLN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Capstone Investment Advisors's MOLN Position: Q3 2021 in Review

Capstone Investment Advisors sold out of Molecular Partners (MOLN) in Q3 2021, closing a stake of 28,741 shares — an estimated $589K sold.

Capstone Investment Advisors first reported a position in MOLN in Q2 2021 and held it in 1 quarter. The position peaked at $589K in Q2 2021. 9 funds tracked by Wall St. Rank hold MOLN as of Q3 2021.

  • Capstone Investment Advisors reported no remaining Molecular Partners position as of Q3 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 28,741 Molecular Partners shares in Q3 2021, an estimated $589K.
  • Capstone Investment Advisors first reported a position in Molecular Partners in Q2 2021 and held it in 1 quarter.
  • Capstone Investment Advisors's Molecular Partners position peaked at $589K in Q2 2021.
  • 9 funds tracked by Wall St. Rank held Molecular Partners as of Q3 2021.

Based on Capstone Investment Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.